Regional cerebral THK5351 accumulations correlate with neuropsychological test scores in Alzheimer continuum
暂无分享,去创建一个
[1] L. Ai,et al. Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer’s Disease , 2022, Frontiers in Aging Neuroscience.
[2] Y. Kimura,et al. Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer’s disease , 2021, Japanese Journal of Radiology.
[3] M. Mintun,et al. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. , 2021, Journal of Alzheimer's disease : JAD.
[4] Y. Kimura,et al. Regional gray matter-dedicated SUVR with 3D-MRI detects positive amyloid deposits in equivocal amyloid PET images , 2020, Annals of Nuclear Medicine.
[5] H. Matsuda,et al. Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET , 2019, Japanese Journal of Radiology.
[6] Stephen F. Carter,et al. Astrocyte Biomarkers in Alzheimer's Disease. , 2019, Trends in molecular medicine.
[7] Christopher G Schwarz,et al. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease , 2018, Human brain mapping.
[8] Clifford R. Jack,et al. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable , 2018, Alzheimer's & Dementia.
[9] H. Arai,et al. Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease , 2017, The Journal of Nuclear Medicine.
[10] H. Nishida,et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI , 2016, Physics in medicine and biology.
[11] H. Arai,et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[12] Takamichi Murakami,et al. Investigation of 11C-PiB equivocal PET findings , 2015, Annals of Nuclear Medicine.
[13] K. Ishii. PET Approaches for Diagnosis of Dementia , 2014, American Journal of Neuroradiology.
[14] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[15] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[16] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[17] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[18] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[19] Gianmario Sambuceti,et al. Unawareness of memory deficit in amnestic MCI: FDG-PET findings. , 2010, Journal of Alzheimer's disease : JAD.
[20] W. Klunk,et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.
[21] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[22] Vijaya L. Melnick,et al. Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.